Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Sponsor: Miltenyi Biomedicine GmbH
Summary
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Official title: A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a North American Miltenyi Biomedicine-Sponsored Clinical Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2024-05-15
Completion Date
2041-12-01
Last Updated
2026-08-05
Healthy Volunteers
No
Conditions
Interventions
Long-term Follow-Up
No intervention
Locations (11)
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Stanford University
Stanford, California, United States
Yale University
New Haven, Connecticut, United States
Robert H Lurie Cancer Center
Chicago, Illinois, United States
University of Kansas Cancer Center
Westwood, Kansas, United States
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Duke University Medical Center - Division of Hematologic Malignancies
Durham, North Carolina, United States
Oregon Health and Science University Knight Cancer Institute
Portland, Oregon, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States